Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lifted by XTX Topco Ltd

Key Points

• XTX Topco Ltd increased its stake in Regeneron Pharmaceuticals by 74.9%, now holding a total of 3,638 shares valued at approximately $2.3 million.
• Several institutional investors have acquired stakes in Regeneron recently, with 83.31% of the stock currently owned by institutional investors.
• Regeneron reported Q1 EPS of $8.22, missing estimates, and declared a quarterly dividend of $0.88 per share, yielding 0.63%.

XTX Topco Ltd raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 74.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,638 shares of the biopharmaceutical company's stock after buying an additional 1,558 shares during the quarter. XTX Topco Ltd's holdings in Regeneron Pharmaceuticals were worth $2,307,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Pamalican Asset Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $4,915,000. Rhenman & Partners Asset Management AB lifted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after purchasing an additional 4,457 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after purchasing an additional 955 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on REGN shares. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Citigroup reaffirmed a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Morgan Stanley reissued an "overweight" rating on shares of Regeneron Pharmaceuticals in a research report on Friday. Finally, Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $13.41 during trading on Friday, reaching $558.87. The stock had a trading volume of 1,656,418 shares, compared to its average volume of 858,977. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a market cap of $60.34 billion, a PE ratio of 14.23, a P/E/G ratio of 2.05 and a beta of 0.33. The firm's 50 day moving average price is $538.05 and its two-hundred day moving average price is $604.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the firm posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.